Choosing First-Line Therapy in HER2+ Metastatic Disease

First-line HER2-positive treatment is no longer one-size-fits-all.

This clip walks through how clinicians are stratifying patients based on hormone receptor status, disease-free interval, CNS involvement, visceral burden, and molecular features to choose the right regimen upfront.